//
AIM2-driven inflammasome activation in heart failure
Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced
A population-based study of 92 clinically recognised risk factors for heart failure: co-occurrence, prognosis and preventive potential
Clinical epidemiology of heart failure with preserved ejection fraction (HFpEF) in comparatively young hospitalized patients
Prdm16 Deficiency Leads to Age-Dependent Cardiac Hypertrophy, Adverse Remodeling, Mitochondrial Dysfunction, and Heart Failure
Lateral Wall Dysfunction Signals Onset of Progressive Heart Failure in Left Bundle Branch Block
Natriuretic Peptide-Guided Heart Failure Therapy After the GUIDE-IT Study
A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation